EMMA | tickerfilter.com

Fundamental analysis

19%

Profitability 8%

Dept financing 13%

Liquidity 49%

Performance 25%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

200.00%

1 Month

-88.00%

3 Months

-99.67%

6 Months

-99.75%

1 Year

-99.81%

2 Year

-99.92%

Key data

Stock price

$0.00

P/E Ratio

0.00

DAY RANGE

N/A - N/A

EPS

$0.00

52 WEEK RANGE

$0.00 - $0.17

52 WEEK CHANGE

-$1.00

MARKET CAP

19.160 K

YIELD

N/A

SHARES OUTSTANDING

63.866 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

N/A

BETA

0.00

PUBLIC FLOAT

AVERAGE 10 VOLUME

$1,200

AVERAGE 30 VOLUME

$322,892

Company detail

CEO: Yutaka Niihara
Region: US
Website: https://www.emmausmedical.com/
Employees: 50
IPO year: -

Issue type: Common Stock
Market: NASDAQ
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services

emmaus life sciences, inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of innovative treatments and therapies primarily for rare and orphan disease. we are initially focusing our product development efforts in sickle cell disease, a genetic disorder. our lead product candidate is an oral pharmaceutical grade l-glutamine treatment that demonstrated positive clinical results in our completed phase 3 clinical trial for sickle cell anemia and sickle ß0-thalassemia.

EMMA - Emmaus Life Sciences Inc.